| Literature DB >> 33532307 |
Cameron J Britton1, Bridget L Findlay1, Niki Parikh1, Tobias Kohler1, Sevann Helo1, Matthew J Ziegelmann1.
Abstract
BACKGROUND: Novel strategies have been proposed to minimize postoperative opioid use, yet many patients experience significant pain after penile surgery. Our objective was to evaluate postoperative opioid use in patients undergoing penile ring block with long-acting liposomal bupivacaine (LB; Exparel) during surgery for Peyronie's disease (PD).Entities:
Keywords: Plication; Xiaflex; collagenase; incision and grafting; penile traction
Year: 2021 PMID: 33532307 PMCID: PMC7844478 DOI: 10.21037/tau-20-871
Source DB: PubMed Journal: Transl Androl Urol ISSN: 2223-4683
Figure 1Illustration demonstrating our technique for penile ring block involved injection of local anesthesia along the dorsal (A), lateral (B), and ventral (C) aspects of the penile shaft.
Patient baseline demographics
| Total cohort (n=28) | |
|---|---|
| Age, median (range) | 56 (18–70) |
| PD symptom duration (months), median (range) | 24 (9–72) |
| Baseline subjective erectile dysfunction*, n (%) | 6 (21) |
| Subjective penile shortening, n (%) | 23 (82) |
| Preceding penile trauma, n (%) | 8 (29) |
| Medical comorbidities, n (%) | |
| Diabetes | 4 (14) |
| Hypertension | 8 (29) |
| Hyperlipidemia | 6 (21) |
| Coronary artery disease | 1 (4) |
| Prior PD treatments | |
| Intralesional collagenase, n (%) | 10 (36) |
| Penile traction, n (%) | 6 (21) |
| Objective curvature assessment | |
| Baseline curvature (degrees), median (range) | 60 (35–105) |
| Curvature direction, n (%) | |
| Dorsal | 6 (21) |
| Ventral | 3 (11) |
| Lateral | 2 (7) |
| Biplanar | 17 (61) |
| Indentation/hourglass deformity, n (%) | 16 (57) |
| Hinge-effect, n (%) | 11 (39) |
| Surgery performed, n (%) | |
| Tunica albuginea plication | 18 (64) |
| Partial plaque excision and grafting | 10 (36) |
*, Responsive to oral phosphodiesterase-5 inhibitors.
Patient-specific opioid consumption
| Age | PD duration (months) | Baseline ED | Curve | Curve (degrees) | Indentation/hourglass | Hinge-effect | Prior CCH | Prior PTT | Procedure | Oxycodone tablets (5 mg) utilized | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| POD #1 | POD #2 | POD #3 | POD #4 | POD #5 | Total | |||||||||||
| 1 | 59 | 48 | Yes | Dorsolateral | 55 | No | No | Yes | No | TAP | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 59 | 40 | No | Ventral | 40 | No | No | Yes | Yes | TAP | 1 | 1 | 1 | 2 | 5 | 10 |
| 3 | 50 | 12 | No | Dorsal | 55 | Yes | Yes | Yes | No | PEG | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | 62 | 14 | No | Dorsolateral | 65 | No | No | Yes | Yes | TAP | 0 | 0 | 0 | 0 | 0 | 0 |
| 5 | 64 | 30 | Yes | Dorsal | 55 | Yes | No | No | No | TAP | 0 | 0 | 0 | 0 | 0 | 0 |
| 6 | 55 | 30 | No | Left | 105 | Yes | Yes | No | No | PEG | 0 | 0 | 0 | 0 | 0 | 0 |
| 7 | 60 | 36 | Yes | Dorsolateral | 60 | Yes | No | No | No | TAP | 0 | 0 | 0 | 0 | 0 | 0 |
| 8 | 51 | 60 | Yes | Left | 35 | No | No | No | No | TAP | 0 | 0 | 0 | 0 | 0 | 0 |
| 9 | 57 | 24 | No | Dorsolateral | 55 | Yes | No | No | No | TAP | 0 | 0 | 0 | 0 | 0 | 0 |
| 10 | 50 | 24 | Yes | Dorsal | 40 | No | No | Yes | No | TAP | 0 | 0 | 0 | 0 | 0 | 0 |
| 11 | 55 | 36 | No | Dorsal | 60 | Yes | Yes | No | No | PEG | 0 | 0 | 0 | 0 | 0 | |
| 12 | 64 | 12 | No | Dorsolateral | 70 | No | Yes | Yes | Yes | TAP | 0 | 0 | 4 | 1 | 0 | 5 |
| 13 | 61 | 24 | No | Dorsolateral | 85 | Yes | Yes | Yes | Yes | PEG | 0 | 0 | 0 | 1 | 0 | 1 |
| 14 | 61 | 9 | No | Dorsolateral | 90 | Yes | Yes | No | No | PEG | 0 | 0 | 0 | 1 | 0 | 2 |
| 15 | 51 | 36 | No | Dorsolateral | 85 | Yes | Yes | No | No | PEG | 0 | 0 | 0 | 0 | 0 | 0 |
| 16 | 50 | 20 | No | Dorsolateral | 105 | Yes | Yes | Yes | No | PEG | 0 | 0 | 0 | 2 | 2 | 4 |
| 17 | 18 | 48 | No | Ventral | 90 | No | No | No | No | TAP | 1 | 1 | 1 | 0 | 0 | 3 |
| 18 | 50 | 10 | No | Dorsal | 60 | No | No | No | No | TAP | 0 | 0 | 1 | 1 | 0 | 2 |
| 19 | 70 | 42 | No | Dorsal | 50 | Yes | No | Yes | Yes | TAP | 0 | 0 | 1 | 1 | 1 | 3 |
| 20 | 51 | 12 | No | Ventral | 65 | Yes | Yes | No | No | PEG | 0 | 0 | 0 | 0 | 0 | 0 |
| 21 | 22 | 48 | No | Ventrolateral | 90 | No | No | No | Yes | TAP | 0 | 0 | 0 | 1 | 1 | 2 |
| 22 | 55 | 12 | Yes | dorsolateral | 60 | No | No | Yes | No | TAP | 0 | 0 | 0 | 0 | 0 | 0 |
| 23 | 56 | 72 | No | Dorsolateral | 50 | Yes | No | No | No | TAP | 0 | 0 | 0 | 0 | 0 | 0 |
| 24 | 65 | 12 | No | Dorsolateral | 70 | Yes | No | No | No | TAP | 0 | 0 | 0 | 0 | 0 | 0 |
| 25 | 55 | 24 | No | Dorsolateral | 90 | Yes | Yes | No | No | PEG | 0 | 0 | 0 | 0 | 0 | 0 |
| 26 | 57 | 24 | No | Dorsolateral | 60 | Yes | No | No | No | TAP | 0 | 0 | 0 | 0 | 0 | 0 |
| 27 | 58 | 11 | No | Dorsolateral | 100 | Yes | Yes | No | No | PEG | 0 | 0 | 0 | 0 | 0 | 0 |
| 28 | 56 | 12 | No | Dorsolateral | 60 | No | No | No | No | TAP | 0 | 0 | 0 | 0 | 0 | 0 |
ED, erectile dysfunction, responsive to phosphodiesterase-5 inhibitors; CCH, collagenase Clostridium histolyticum (Xiaflex; Endo pharmaceuticals, Dublin, Ireland); PTT, penile traction therapy; POD, postoperative day; TAP, tunica albuginea plication; PEG, partial plaque excision and grafting,